- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03542877
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Tucson, Arizona, Verenigde Staten, 85724
- University of Arizona
-
-
California
-
Los Angeles, California, Verenigde Staten, 90033
- Kenneth Norris Jr. Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Universtiy of Colorado Denver
-
Lone Tree, Colorado, Verenigde Staten, 80124
- Lone Tree Health Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital Cancer Center
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
-
Pennsylvania
-
Abington, Pennsylvania, Verenigde Staten, 19001
- Jefferson Abington Hospital
-
Philadelphia, Pennsylvania, Verenigde Staten, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Thomas Jefferson University
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98122
- Swedish Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- The subject has a histologic or cytologic diagnosis of colorectal adenocarcinoma that is metastatic or unresectable and is refractory to or progressed (or relapsed) following a fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab; prior epidermal growth factor inhibitor therapy is required for patients with left-sided, RAS wild-type tumors; prior FDA-approved PD-1 inhibitor therapy is required for patients with MSI-H colorectal cancer. Prior regorafenib or TAS-102 treatment is not required.
- Measurable disease per RECIST 1.1 as determined by the investigator.
- The subject has had an assessment of all known disease sites e.g., by computerized tomography (CT) scan and/or magnetic resonance imaging (MRI) within 28 days before the first dose of cabozantinib.
- The subject is ≥ 18 years old on the day of consent.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Recovery to baseline or ≤ Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
- Adequate archival frozen or fixed tissue available from primary or metastatic site for genotypic analysis (at least 15 unstained slides and/or tumor block).
The subject has organ and marrow function and laboratory values as follows within 7 days before the first dose of cabozantinib:
- ANC ≥ 1500/mm3 without colony stimulating factor support;
- Platelets ≥ 100,000/mm3;
- Hemoglobin ≥ 9 g/dL;
- Bilirubin ≤ 1.5 x ULN. For subjects with known Gilbert's disease, bilirubin ≤ 3.0 mg/dL;
- Serum albumin ≥ 2.8 g/dl;
Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min. For creatinine clearance estimation, the Cockcroft and Gault equation should be used:
- Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72);
- Female: Multiply above result by 0.85;
- ALT and AST ≤ 3.0 x ULN;
- Lipase < 2.0 x the upper limit of normal and no radiologic or clinical evidence of pancreatitis;
- UPCR ≤ 1;
- Serum phosphorus, calcium, magnesium and potassium ≥ LLN.
- The subject is capable of understanding and complying with the protocol requirements and has signed the informed consent document.
- Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s).
Exclusion Criteria:
- The subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment;
- Prior treatment with cabozantinib;
- Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before the first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible;
- Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 14 days before the first dose of study treatment. Note: Subjects with prostate cancer currently receiving LHRH or GnRH agonists may be maintained on these agents;
- The subject has received any other type of investigational agent within 28 days before the first dose of study treatment;
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before the first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of the start of study treatment;
- The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 7 days before the first dose of study treatment;
- Concomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel); Note: Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimen. ;
The subject has experienced any of the following:
- clinically-significant GI bleeding within 6 months before the first dose of study treatment;
- hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment;
- any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment.
- The subject has radiographic evidence of cavitating pulmonary lesion(s);
- The subject has tumor invading or encasing any major blood vessels;
- The subject has evidence of clinically significant bleeding from tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib;
The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:
a. Cardiovascular disorders including: i. Congestive heart failure (CHF): New York Heart Association (NYHA) Class III (moderate) or Class IV (severe) at the time of screening; ii. Concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 150 mm Hg systolic or > 100 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment; iii. Any history of congenital long QT syndrome; iv. Any of the following within 6 months before the first dose of study treatment:
- unstable angina pectoris;
- clinically-significant cardiac arrhythmias;
- stroke (including transient ischemic attack (TIA), or other ischemic event);
- myocardial infarction;
thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena cava filter) are not eligible for this study).
b. GI disorders particularly those associated with a high risk of perforation or fistula formation including: i. Active peptic ulcer disease, inflammatory bowel disease (eg, Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis or acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction ii. Abdominal fistula, GI perforation, bowel obstruction, intra-abdominal abscess within 6 months before randomization, Note: Complete healing of an intra-abdominal abscess must be confirmed prior to randomization c. Other clinically significant disorders that would preclude safe study participation;
- Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible;
QTcF > 500 msec within 1 month before the first dose of study treatment:
a. Three ECGs must be performed for eligibility determination. If the average of these three consecutive results for QTcF is ≤ 500 msec, the subject meets eligibility in this regard.
- Pregnant or lactating females;
- Inability to swallow intact tablets;
- Previously identified allergy or hypersensitivity to components of the study treatment formulations;
- Diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy;
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Oral Cabozantinib
Patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks.
If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
|
Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks.
This medication should be taken on an empty stomach.
Patients should not eat 2 hours before or 1 hour after taking cabozantinib.
Only water is permitted during this 3 hour time frame.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
12-Week Progression Free Survival
Tijdsspanne: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
A patient is classified as progression-free if s/he is assessed as not having progressive disease (PD) as defined per RECIST 1.1 criteria at either the 12-week assessment or after having at least 11 weeks of treatment for subjects without the 12-week assessment. Censored patients (i.e. those who have not progressed but who are missing a 12-week assessment) are not included in the analysis. Subjects who didn't have the 12-week assessment but who had clinical progression were included and considered to have progressed. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
12-Week Progression-Free Survival by RAS Mutation Status
Tijdsspanne: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
This has the same outcome measure description as the primary analysis.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0)
for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
12-Week Progression-Free Survival by PIK3CA Mutation Status
Tijdsspanne: This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
This has the same outcome measure description as the primary analysis.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0)
for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
This outcome was assessed at the 12-week assessment. Subjects without the 12-week assessment but who had at least 11 weeks of treatment were included.
|
Progression-Free Survival (PFS)
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
Progression-free survival will be defined as the time from administration of the initial dose of cabozantinib to evidence of radiographic progression as defined by RECIST criteria or death from any cause without evidence of disease progression, whichever occurs first. Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Progression-Free Survival (PFS) by RAS Mutation Status
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
This has the same outcome measure description as the PFS analysis.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0)
for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Progression-Free Survival (PFS) by PIK3CA Mutation Status
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
This has the same outcome measure description as the PFS analysis.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.0)
for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Response Rate in Patients With CRC Treated With Cabozantinib
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
*A patient is classified as a responder if s/he is assessed as having complete response or partial response (CR or PR) at the time of any assessment, where CR and PR are defined per RECIST 1.1 criteria.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Overall Survival (OS) in Patients With CRC Treated With Cabozantinib
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
Overall Survival will be defined as the time from administration of the initial dose of cabozantinib until death from any cause.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Overall Survival (OS) by RAS Mutation Status
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
This has the same outcome measure description as the OS analysis.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Overall Survival (OS) by PIK3CA Mutation Status
Tijdsspanne: Study start date to study end date, or death, whichever comes first, up to 24 months
|
This has the same outcome measure description as the OS analysis.
|
Study start date to study end date, or death, whichever comes first, up to 24 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 18-0021.cc
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Colorectale kanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Nog niet aan het wervenAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Oral Tablet: Cabozantinib
-
Alfredo BerrutiWervingCarcinoom ProstaatItalië
-
ExelixisActief, niet wervendMedullaire schildklierkankerAustralië, Frankrijk, Israël, Spanje, Russische Federatie, Nederland, Hongarije, Korea, republiek van, Kroatië, Italië, Canada, Polen, Roemenië, Zweden
-
Institut für Klinische Krebsforschung IKF GmbH...Johann Wolfgang Goethe University Hospital, Prof. Dr. med. TrojanActief, niet wervendHepatocellulair carcinoom (HCC) | Tweedelijns behandelingDuitsland
-
Istituto Oncologico Veneto IRCCSWervingColorectaal adenocarcinoomItalië
-
University of North Carolina, Chapel HillVoltooid
-
University of BolognaIpsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... en andere medewerkersOnbekendNiet-kleincellige longkankerItalië
-
ExelixisVoltooidKanker | NSCLC | Vaste tumorenJapan
-
Hasan Kalyoncu UniversityVoltooidVoortijdige geboorte | Voedingsgedrag | ZuiggedragKalkoen
-
Universitaire Ziekenhuizen KU LeuvenVoltooid
-
University of BrasiliaVoltooid